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VariantAbstract
Molecular monitoring of BCR–ABL1 transcript levels using quantitative polymerase chain reac-
tion is an essential part of the modern management of chronic myeloid leukemia patients trea-
ted with tyrosine kinase inhibitors. Establishing the diagnostic BCR–ABL1 fusion transcript is
necessary in order to select appropriate primers and probes for such monitoring. A case is
described in which quantitative polymerase chain reaction failed to detect the presence of
BCR–ABL1 fusion transcript in a Philadelphia chromosome-positive chronic myeloid leukemia
patient. Further investigation demonstrated a novel in-frame BCR–ABL1 fusion transcript with
a breakpoint in BCR exon 13 and insertion of a sequence of ABL1 intron 1, therefore enabling
subsequent molecular monitoring. This case highlights the requirement for characterization
of the BCR–ABL1 transcript type at chronic myeloid leukemia diagnosis. Issues concerning stan-
dardized methodological approaches and interpretation of transcript levels in such rare cases
are discussed.
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Identification of the BCR–ABL1 fusion, the molecular hall-
mark of chronic myeloid leukemia (CML), is an essential ele-
ment of diagnosis. Several qualitative reverse-transcription
polymerase chain reaction (RT-PCR) approaches are able to
detect the common e13a2 (b2a2) and e14a2 (b3a2) BCR–
ABL1 transcripts and the majority of the less frequent, vari-
ant transcript types [1–3]. Less than 5% of CML cases express
these atypical BCR–ABL1 transcripts which arise from alter-
native splicing of BCR or ABL1 exons, breakpoints within
exons, or insertion and/or deletions [4]. These atypical
BCR–ABL1 fusion transcripts are associated with particular
phenotypes and responses to tyrosine kinase inhibitors (TKI)
[5,6]. Characterization of the BCR–ABL1 fusion transcript
type at presentation is necessary to allow selection of appro-
priate primer/probe combinations for real-time quantitative
PCR (qPCR) monitoring that provides information on kinetics
of response to TKI therapy. Attainment of molecular
responses at defined time points is becoming increasingly
used to guide subsequent treatment strategies [7,8]. A case
of Philadelphia chromosome-positive (Ph+) CML is described
in which a qPCR screening method failed to detect a
BCR–ABL1 fusion, prompting the characterization of a novel
variant BCR–ABL1 fusion transcript, thus affording the
opportunity for prospective molecular monitoring.Case report
A 44-year-old man presented incidentally with a white blood
cell count of 103.6  109/L, hemoglobin of 12.6 g/dL, and
platelets of 113  109/L. The patient had a raised lactate
dehydrogenase of 769 IU/L. The bone marrow aspirate dis-
played marked myeloid hyperplasia with no excess of blasts
indicative of chronic phase CML. Cytogenetic G-band analy-
sis identified a t(9;22)(q34;q11.2) in 19/20 metaphases ana-Figure 1 Sequence of a typical e13a2 BCR–ABL1 transcript. (A
nucleotides (purple), and quantitative polymerase chain reaction
transcript of patient depicting insertion of 20 nucleotides (red) fro
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BCR/ABL1 probe set (Cytocell, Cambridge, UK) detected a
BCR–ABL1 fusion in 180 out of 200 cells examined, which
would be consistent with the G-band results. Molecular
screening using a widely adopted qPCR approach failed to
detect BCR–ABL1 transcripts [9]. Qualitative RT-PCR using
standardized primers BCR-b1-A and ABL-a3-B that amplify
the common BCR–ABL1 fusion transcripts were employed
and amplified a product smaller than that expected for an
e13a2 BCR–ABL1 transcript [2]. Sanger sequencing of this
product showed a breakpoint within BCR exon 13 with dele-
tion of 53 nucleotides that included the forward qPCR BCR
primer ENF501 annealing site and an insertion of 20 nucleo-
tides from ABL1 intron 1 (NC_018920.2; nt 139500-139519)
fused to ABL1 exon a2 [9]. This resulted in an in-frame
fusion transcript (Fig. 1). The patient commenced imatinib,
400 mg oral daily, rapidly achieving a hematological
response. After 3 months of TKI, qPCR was performed using
forward BCR primer BCR-b1-A, the peripheral blood BCR–
ABL1/ABL1 level was 19.2%. Cytogenetic analysis was not
repeated. The patient continues on imatinib, 400 mg oral
daily, with prospective monitoring planned.
Discussion
Variant BCR–ABL1 transcripts occur in <5% of CML patients
with the most commonly reported due to alternative splic-
ing of BCR and ABL1 exons being the e19a2, e8a2, e6a2,
e1a2, e13a3, and e14a3 types, although several others have
been documented. Insertion of ABL1 intron 1 sequence at
the BCR–ABL1 fusion site was first described in a CML
patient due to weak Southern blot probe hybridization
[10]. Molecular characterization of these rare, variant
e13a2 BCR-ABL1 transcripts has revealed deletions that
ablate the real-time qPCR BCR forward primer annealing
site, as in the case described herein. Concomitant insertions
of ABL1 intron 1 sequence are of variable size and always) Arrow depicts breakpoint within BCR exon 13, deleted 53
forward BCR primer annealing site (underlined). (B) Atypical
m ABL1 intron 1.
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functional BCR–ABL1 protein, capable of propagating CML
[11–15].
While qPCR is increasingly used for BCR–ABL1 screening,
this case highlights the requirement for absolute character-
ization of the diagnostic BCR–ABL1 fusion transcript in such
apparent ‘‘false-negative” scenarios. While qualitative RT-
PCR and Sanger sequencing remain useful, emerging next-
generation sequencing technologies have been effective in
identifying such atypical BCR–ABL1 fusions in Ph+ leukemia
[16,17].
Standardization of BCR–ABL1 molecular monitoring for
CML patients by harmonization to an international scale
through creation of a laboratory-specific conversion factor
has been on-going for several years [18,19]. Both the early
molecular response at 3 months and longer-term deep
molecular responses are now being considered valuable in
identifying those CML patients likely to fail first-line TKI
and those eligible for TKI cessation respectively [20,21].
However, these processes have only been applicable to
the common e13a2 and e14a2 BCR–ABL1 transcripts with
no standardized approach for monitoring the rare variant
BCR–ABL1 transcripts available [22]. Standardization would
at least require the establishment of cell lines and creation
of accessible reference panels for each of the notably,
recurring BCR-ABL1 variants from which conversion or cor-
rection could be applied to individual qPCR approaches: a
considerable effort that would require significant collabora-
tion given the low incidence of such variants. Given the sce-
nario described with an international scale unconverted
BCR–ABL1/ABL% of 19.2% at 3 months, this patient would
fall under the warning category as defined by the European
LeukemiaNet (ELN) criteria [7] and possibly considered for a
switch of TKI. If the laboratory-specific conversion factor of
0.58 is applied, then the BCR–ABL1/ABL1% of 11.1% would
approximate that of an ELN-defined optimal response of
610%. In this instance, cytogenetic analysis would have
been additionally informative at this 3-month time point
to distinguish between ELN-defined optimal (635% Ph+)
and warning (36–95% Ph+) categories. Continued conven-
tional cytogenetic analysis and/or fluorescence in situ
hybridization are therefore recommended in such cases.
In conclusion, identification of atypical BCR–ABL1 fusion
transcripts in CML patients is necessary for prospective
monitoring, yet issues remain concerning standardization
of qPCR assays and interpretation of molecular findings.
Documentation of these uncommon BCR–ABL1 variants is
further required in order to define optimal TKI strategies.
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